Barbara Van Rooyan petitions the FDA to recall OxyContin

Barbara Van Rooyan’s petition asked the U.S. Food and Drug Administration to temporarily recall OxyContin until the drug could be reformulated to resist abuse and relabeled for severe pain only. Filed on February 1, 2005, it turned a bereaved mother’s demand for action into a sustained campaign of research, paperwork, testimony, and protest. The account ends not with a decision but with Van Rooyan still waiting for an answer.

Background and Purpose

Van Rooyan’s campaign arose from the death of her son after he took an OxyContin pill given to him by a friend. The friend had reassured him that the medication was FDA-approved and therefore safe. That assurance stayed with Van Rooyan as she researched the drug and prepared her petition: the gap between a medicine’s official approval and the risks she believed families were facing became a central reason to challenge how it was being presented and used.

Her request was specific. She sought a temporary recall, not simply stronger warnings, until OxyContin could be made abuse-resistant and its labeling restricted to severe pain. The proposed sequence mattered: remove the existing product temporarily, change its formulation, and narrow the circumstances under which it was labeled for use. Van Rooyan was not content to leave the question at the level of general concern about prescribing; she wanted the agency to take a concrete regulatory step.

There was already a cautionary precedent. In 2004, the Connecticut attorney general had filed a separate petition asking for stronger OxyContin warnings about the risks of frequent prescribing. That application remained stalled in bureaucratic limbo and was initially rejected in 2008. The two petitions were distinct, but the earlier one showed the difficulty of converting a formal request into timely agency action. Van Rooyan filed her own petition while that wider regulatory process was already moving slowly.

Preparing and Filing the Petition

Van Rooyan approached the filing as a research task as well as an act of grief. She described herself as stubborn and noted her Berkeley degree; the book emphasizes that she was accustomed to doing research. Rather than relying only on personal testimony, she assembled information that could support a case for regulatory intervention. Her husband, a physician, helped her, and she incorporated data gathered by Art Van Zee.

That collaboration answered a practical weakness in Van Zee’s earlier effort. He had spent years treating patients, much of the time in exceptionally long workdays, and had developed a recall petition bearing ten thousand signatures. Yet that earlier petition was never formally submitted to the U.S. Food and Drug Administration. Van Zee later explained that his group had lacked the time, energy, and staff to complete the submission. Van Rooyan’s focus therefore did more than add another voice to the campaign: she brought together existing evidence and completed the filing that the earlier effort had not managed to make.

She submitted the petition on February 1, 2005. The date marks a concrete step, but not a resolution. Filing transferred the request into an administrative process whose demands were themselves formidable. Van Rooyan recalled that the agency’s recall form was long and involved, structured in a way that could discourage people from completing it. Her persistence carried the petition past that threshold, while the stalled Connecticut application offered little reason to expect a quick answer.

Testimony and Public Advocacy

The filing formed one part of a broader campaign. Van Rooyan testified alongside Art Van Zee at U.S. Food and Drug Administration hearings, bringing her experience as a bereaved mother into the same public setting as his years of clinical observation and collected data. The account presents their work as complementary: Van Zee supplied information built through sustained medical practice, while Van Rooyan helped ensure that the evidence was organized and put before the agency.

She also took the issue beyond the hearing room. In her Northern California hometown, she organized a protest outside a continuing-medical-education seminar funded by Purdue Pharma. The seminar was taught by a prominent pain-clinic doctor. By protesting outside a professional education event, Van Rooyan challenged not only the drug’s labeling but also the setting in which medical knowledge about pain treatment and OxyContin was being communicated. The action linked her regulatory demand to a public dispute over the influence surrounding physicians’ education.

Her repeated calls made her familiar to agency staff. An ombudsman told her that staff members all knew who she was, a recognition that conveys how persistently she had pressed the case. Familiarity, however, was not the same as a decision. The petition required her to keep demanding attention from an institution whose processes she had already found difficult to navigate.

Waiting and Significance

After filing, Van Rooyan waited for the U.S. Food and Drug Administration to answer. The narrative stresses the duration rather than supplying a resolution: she waited, and continued waiting. It does not establish that this petition was granted, rejected, or otherwise finally resolved, so its endpoint is the unanswered request itself.

That unresolved ending gives the action its particular force. Van Rooyan had completed what the earlier ten-thousand-signature effort could not: she brought a petition to the agency, supported it with Art Van Zee’s data, testified publicly, and organized a protest. Yet procedural completion did not guarantee a timely response. The contrast between the care she put into making the case and the silence that followed makes delay part of the story, not merely background to it.

The petition also shows how personal loss could become organized public advocacy without ceasing to be personal. The memory of her son’s friend describing the pill as safe had led her toward research; her research became a filing; and the filing grew into testimony and protest. The book does not claim that her efforts alone changed policy. Instead, it records a mother trying to make the agency confront a specific danger, and the uncertainty that remained even after she had done the work required to ask.